Syntropharma
Creating innovative transdermal solutions from proven compounds to enhance clinical profiles and drive pharmaceutical advancement.
Creating innovative transdermal solutions from proven compounds to enhance clinical profiles and drive pharmaceutical advancement.
Syntropharma is a biotechnology and pharmaceutical startup founded in 2005. The company is committed to revolutionizing the pharmaceutical industry by transforming well-known generic compounds into transdermal patch applications. Their slogan, "Creating innovative transdermal solutions from proven compounds to enhance clinical profiles and drive pharmaceutical advancement," encapsulates their mission. In April 2012, TRICAPITAL Angels Limited made a £385.00KVenture Round investment in Syntropharma, highlighting investor confidence in the company's vision and potential. Syntropharma aims to establish a portfolio of groundbreaking transdermal products with strong intellectual property, intending to license them to established pharmaceutical partners, thus positioning themselves as a significant player in driving pharmaceutical advancement.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £385.00K | 1 |
|
16 Apr 2012 |
| Venture Round | $640.00K | 3 |
|
29 Dec 2009 |
| Series B | $2.40M | 3 |
|
15 Sep 2008 |
| Series A | £1.00M | 3 |
|
24 Nov 2006 |
No recent news or press coverage available for Syntropharma.
We care about your data, and we'd love to use cookies make your experience better.
